Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719759 | 0.77 | MMP2 (0.68) | MMP2PKMMAPTRECQLHTT | |
| SCHEMBL1562072 | 0.73 | PARL (0.66) | MMP2PKMMAPTRECQLHTT | |
| SCHEMBL7383735 | 0.71 | MMP2 (0.64) | MMP2PKMMAPTRECQLHTT | |
| SCHEMBL505093 | 0.70 | KMT2A (0.69) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL4537086 | 0.70 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL10724066 | 0.70 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL565301 | 0.70 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL699639 | 0.70 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8203532 | 0.70 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8200466 | 0.70 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112892436-A | Full continuous flow production process of 1-alkyl-5-hydroxypyrazole | 杭州新本立医药有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-109320457-A | The preparation method and device of hydroxypyrazoles | 凯莱英医药化学（阜新）技术有限公司 | 2019-02-12 | — | — | CN | disclosed |
| EP-1127050-B1 | METHOD FOR PRODUCING 1-SUBSTITUTED 5-HYDROXYPYRAZOLES | BASF SE (DE) | 2010-08-25 | — | — | EP | disclosed |
| EP-1131299-B1 | METHOD FOR PRODUCING 1-SUBSTITUTED 5- OR 3-HYDROXYPYRAZOLES | BASF AG (DE) | 2003-09-17 | — | — | EP | disclosed |
| EP-1131298-B1 | METHOD FOR THE PRODUCTION OF 1-SUBSTITUTED 5-HYDROXYPYRAZOLES | BASF AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-6600071-B2 | Starting materials or intermediates and the cyclization of these under suitable reaction conditions to give compounds of the formula I. The intermediates of the formula II are novel. for argrochemicals | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
| US-20030109717-A1 | Preparation of substituted hydroxypyrazoles | GOTZ NORBERT (DE) | 2003-06-12 | — | — | US | disclosed |
| US-6472538-B1 | HIGH YIELD COUPLING, HYDROGENATION AND CYCLIZATION TO FORM CHEMICAL INTERMEDIATES FOR HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
| US-6392058-B1 | REACTING AN ALKYL VINYL ETHER WITH PHOSGENE; FORMING ACYL CHLORIDE; ESTERIFICATION; REACTING WITH HYDRAZINE | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-21 | — | — | US | disclosed |
| US-6329530-B1 | REACTING ALKYL VINYL ETHER WITH PHOSGENE OR PHOSGENE DERIVATIVE TO FORM ACYL CHLORIDE DERIVATIVE; DEHYDROCHLORIANTING TO FORM 3-ALKOXYACRYLOYL CHLORIDE COMPOUND; REACTING WITH ALKYLHYDRAZINE | BASF AKTIENGESELLSCHAFT (DE) | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109717-A1 | Preparation of substituted hydroxypyrazoles | CYC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | MMP2 3638/4885PKM 2454/4885MAPT 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.